Life-threatening motor neurotoxicity in association with bortezomib

Haematologica

Volumn 91, Issue 7, 2006, Pages 1001-

  Gupta, Sunil ^a   Pagliuca, Antonio ^a   Devereux, Steve ^a   Mufti, Ghulam J ^a   Schey, Steve ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Bortezomib; Multiple myeloma; Peripheral neuropathy

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IDARUBICIN; IMMUNOGLOBULIN G; MELPHALAN; METHYLPREDNISOLONE; VINCRISTINE;

ABDOMINAL DISTENSION; ADULT; AGED; ANAMNESIS; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; KIDNEY FAILURE; MOTOR DYSFUNCTION; MULTIPLE MYELOMA; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; RECURRENT DISEASE; URINE RETENTION;

AGED; BORONIC ACIDS; CRITICAL ILLNESS; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; NEUROTOXICITY SYNDROMES; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES;

EID: 33745796715     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-9.
2. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-75.
3. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84.
4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high dose dexamethasone for relapsed multiple myeloma. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. N Engl J Med 2005;352:2487-98.